Pharmacokinetic study of zonisamide in patients undergoing brain surgery

Ichiro Ieiri, Takato Morioka, Sonyori Kim, Shunji Nishio, Masashi Fukui, Shun Higuchi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To test whether the concentration of the anticonvulsant zonisamide in erythrocytes reflects the brain concentration and the clinical response of the drug, its pharmacokinetics were studied in nine patients undergoing surgery for brain tumour. Erythrocyte, total, and free serum concentrations in samples drawn on the day of brain surgery were compared with levels on a day after the operation. In three patients zonisamide and its major metabolite, 2-sulphamoylacetylphenol, were also analysed in urine. The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 ml kg-1 h-1 P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h -1 on the post-operation day, n = 3). Zonisamide distribution was also altered by the operative procedure, as evidenced by a higher volume of distribution (1.48 compared with 0.87 Lkg-1, P < 0.05, n = 9). The binding of zonisamide was characterized on both days. Zonisamide binding to erythrocytes seemed to occur by two processes: a saturable process and a non-saturable linear process. The maximum binding capacity to erythrocytes (31.6 vs 29.7 μgmL-1) did not differ on the two days; however, increases in the dissociation binding constant (+28%) and the proportionality constant (±24%) were observed on the day of the operation, suggesting that the zonisamide concentration in erythrocytes was greater on the day of the operation. Brain surgery appears to be one of the possible factors altering the rate of elimination of zonisamide and the uptake of the drug by erythrocytes.

Original languageEnglish
Pages (from-to)1270-1275
Number of pages6
JournalJournal of Pharmacy and Pharmacology
Volume48
Issue number12
DOIs
Publication statusPublished - Jan 1 1996

Fingerprint

zonisamide
Pharmacokinetics
Erythrocytes
Brain
Area Under Curve
Operative Surgical Procedures
Serum
Ambulatory Surgical Procedures
Brain Neoplasms
Pharmaceutical Preparations
Anticonvulsants

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacokinetic study of zonisamide in patients undergoing brain surgery. / Ieiri, Ichiro; Morioka, Takato; Kim, Sonyori; Nishio, Shunji; Fukui, Masashi; Higuchi, Shun.

In: Journal of Pharmacy and Pharmacology, Vol. 48, No. 12, 01.01.1996, p. 1270-1275.

Research output: Contribution to journalArticle

Ieiri, Ichiro ; Morioka, Takato ; Kim, Sonyori ; Nishio, Shunji ; Fukui, Masashi ; Higuchi, Shun. / Pharmacokinetic study of zonisamide in patients undergoing brain surgery. In: Journal of Pharmacy and Pharmacology. 1996 ; Vol. 48, No. 12. pp. 1270-1275.
@article{fc964b6b49674ec1857b2e818c00bd84,
title = "Pharmacokinetic study of zonisamide in patients undergoing brain surgery",
abstract = "To test whether the concentration of the anticonvulsant zonisamide in erythrocytes reflects the brain concentration and the clinical response of the drug, its pharmacokinetics were studied in nine patients undergoing surgery for brain tumour. Erythrocyte, total, and free serum concentrations in samples drawn on the day of brain surgery were compared with levels on a day after the operation. In three patients zonisamide and its major metabolite, 2-sulphamoylacetylphenol, were also analysed in urine. The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 ml kg-1 h-1 P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h -1 on the post-operation day, n = 3). Zonisamide distribution was also altered by the operative procedure, as evidenced by a higher volume of distribution (1.48 compared with 0.87 Lkg-1, P < 0.05, n = 9). The binding of zonisamide was characterized on both days. Zonisamide binding to erythrocytes seemed to occur by two processes: a saturable process and a non-saturable linear process. The maximum binding capacity to erythrocytes (31.6 vs 29.7 μgmL-1) did not differ on the two days; however, increases in the dissociation binding constant (+28{\%}) and the proportionality constant (±24{\%}) were observed on the day of the operation, suggesting that the zonisamide concentration in erythrocytes was greater on the day of the operation. Brain surgery appears to be one of the possible factors altering the rate of elimination of zonisamide and the uptake of the drug by erythrocytes.",
author = "Ichiro Ieiri and Takato Morioka and Sonyori Kim and Shunji Nishio and Masashi Fukui and Shun Higuchi",
year = "1996",
month = "1",
day = "1",
doi = "10.1111/j.2042-7158.1996.tb03935.x",
language = "English",
volume = "48",
pages = "1270--1275",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "12",

}

TY - JOUR

T1 - Pharmacokinetic study of zonisamide in patients undergoing brain surgery

AU - Ieiri, Ichiro

AU - Morioka, Takato

AU - Kim, Sonyori

AU - Nishio, Shunji

AU - Fukui, Masashi

AU - Higuchi, Shun

PY - 1996/1/1

Y1 - 1996/1/1

N2 - To test whether the concentration of the anticonvulsant zonisamide in erythrocytes reflects the brain concentration and the clinical response of the drug, its pharmacokinetics were studied in nine patients undergoing surgery for brain tumour. Erythrocyte, total, and free serum concentrations in samples drawn on the day of brain surgery were compared with levels on a day after the operation. In three patients zonisamide and its major metabolite, 2-sulphamoylacetylphenol, were also analysed in urine. The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 ml kg-1 h-1 P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h -1 on the post-operation day, n = 3). Zonisamide distribution was also altered by the operative procedure, as evidenced by a higher volume of distribution (1.48 compared with 0.87 Lkg-1, P < 0.05, n = 9). The binding of zonisamide was characterized on both days. Zonisamide binding to erythrocytes seemed to occur by two processes: a saturable process and a non-saturable linear process. The maximum binding capacity to erythrocytes (31.6 vs 29.7 μgmL-1) did not differ on the two days; however, increases in the dissociation binding constant (+28%) and the proportionality constant (±24%) were observed on the day of the operation, suggesting that the zonisamide concentration in erythrocytes was greater on the day of the operation. Brain surgery appears to be one of the possible factors altering the rate of elimination of zonisamide and the uptake of the drug by erythrocytes.

AB - To test whether the concentration of the anticonvulsant zonisamide in erythrocytes reflects the brain concentration and the clinical response of the drug, its pharmacokinetics were studied in nine patients undergoing surgery for brain tumour. Erythrocyte, total, and free serum concentrations in samples drawn on the day of brain surgery were compared with levels on a day after the operation. In three patients zonisamide and its major metabolite, 2-sulphamoylacetylphenol, were also analysed in urine. The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 ml kg-1 h-1 P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h -1 on the post-operation day, n = 3). Zonisamide distribution was also altered by the operative procedure, as evidenced by a higher volume of distribution (1.48 compared with 0.87 Lkg-1, P < 0.05, n = 9). The binding of zonisamide was characterized on both days. Zonisamide binding to erythrocytes seemed to occur by two processes: a saturable process and a non-saturable linear process. The maximum binding capacity to erythrocytes (31.6 vs 29.7 μgmL-1) did not differ on the two days; however, increases in the dissociation binding constant (+28%) and the proportionality constant (±24%) were observed on the day of the operation, suggesting that the zonisamide concentration in erythrocytes was greater on the day of the operation. Brain surgery appears to be one of the possible factors altering the rate of elimination of zonisamide and the uptake of the drug by erythrocytes.

UR - http://www.scopus.com/inward/record.url?scp=0030448185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030448185&partnerID=8YFLogxK

U2 - 10.1111/j.2042-7158.1996.tb03935.x

DO - 10.1111/j.2042-7158.1996.tb03935.x

M3 - Article

C2 - 9004190

AN - SCOPUS:0030448185

VL - 48

SP - 1270

EP - 1275

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 12

ER -